Track Record
Track Record
Phase Ther­a­peu­tic areaIndi­ca­tionNum­ber of subjectsStudy designRecruit­ment accomplished
0 Micro-​DosingCNSAlzheimer26 AD/​HVPET (Positron Emis­sion Tomog­ra­phy) (proof of mechanism)Yes, pre­ma­ture ending
0 Micro-​DosingCNSMS10 MS/​HVPET(proof of mechanism)Yes
0CNSHuntington´s Dis­easeUp to 45 HVPET Imag­ingOngo­ing
I FIM(First in Man)Meta­bolicOver­weight32 HVPhar­ma­co­ki­netic, dose escalationYes
I FIMRenalOver active bladder56 ElderlyDose find­ing studyYes
I FIMGITChron´s Dis­ease65 HV/​CDPhar­ma­co­ki­neticYes
I FIMImmunol­ogyPer­tus­sis48 HVDose esca­la­tionyes
I FIMNeu­rol­ogyAlzheimer Dis­ease6 HVPETYes
I FIMNeu­rol­ogySchiz­o­phre­nia7 HVPET Val­i­da­tionYes
I FIMImmunol­ogyVac­cine adjuvant130 HVSafety and efficacyYes
I FIMNeu­rol­ogyAlzheimer24 AD/​HVPETYes
I FIMNeu­rol­ogySchiz­o­phre­nia12 HVSafety and tolerabilityYes
IMeta­bolicAnti inflam­ma­tory32 HVPhar­ma­co­ki­net­ics and bioavailabilityYes
IHema­tol­ogyTrans­plan­ta­tion32 HVPhar­ma­co­ki­netic, admin­stra­tion optimizationYes
INeu­rol­ogyInsom­nia18 HVThree-​period cross-​overYes
INeu­rol­ogyMigrain16 HVBioavail­abil­ityYes
INeu­rol­ogyADHD18 HVPET Imag­ingYes
IHuman Phar­ma­col­ogyReplace­ment therapy16 HVPhar­ma­co­ki­netic Yes
INeu­rol­ogyPro­ce­dural analgesia12 HVPhar­ma­co­ki­netic , cross overYes
IMeta­bolicGHD(Hormone Meta­bolic Deficiency)3 GHDPhar­ma­co­ki­net­icsYes
INeu­rol­ogyCNS Occu­pancy4 HVPETYes
INeu­rol­ogyParkinson´s Dis­ease14 PD/​HVPETYes
INeu­rol­ogyAnx­i­ety8 HVPET Effi­cacyYes
IMeta­bolicOral Insulin10 HVDose responseYes
INeu­rol­ogyAlzheimer1015 AD/​HVPET Proof of mechanismPre­ma­ture ending
IMeta­bolicOral Insulin32 Dia­betes 2Dose-​toleranceYes
INeu­rol­ogy /​Pain72 HV/​ElderlyPhar­ma­co­ki­neticYes
INeu­rol­ogyADHD12 HVMRI Val­i­da­tion studyYes
IMeta­bolicOral Insulin8 HVPhar­ma­co­ki­neticYes
INeu­rol­ogyAnx­i­ety20 HVPhar­mo­co­ki­neticWith­drawn
IPsy­chi­atricSchiz­o­phre­nia12 HVPET Imag­ingYes
IMetabolic/​pediatricGHD2 chil­drenYes
IGITBowel cleans­ing80 HVChange in blood chemistryYes
I/​IIaImmunol­ogyBirch pollen allergy36 AllergyDose esca­la­tionYes
IIMeta­bolicGHD12 GHDPhar­ma­co­ki­netic and pharmacodynamicYes
IINeuroNico­tine replacement150 HVPhar­ma­co­dy­namicYes only 120 was needed
IIMeta­bolicGHD8 GHDPhar­mo­co­ki­netic and PharmacodynamicYes
IINutrionLim­i­ta­tions in phys­i­cal functioning70 ElderlyOGTTYes
IIImmunol­ogyHepati­tis B vaccine3 HVSafety and tolerabilityyes
IIGeri­atricMus­cle Weakness6 ElderlyVit­a­min supplementYes
IIaGITUlcer­a­tive Colitis4 UCPhar­ma­co­ki­neticNo
IIbMeta­bolicOver­weight10 HVSafety and efficacyyes
IIIMeta­bolicOver­weight9 HVSafety and efficacyyes
III-​IVCar­di­ol­ogyOdon­tol­ogy20 HV/​CardiacYes
Med techDeviceCatheter Mate­r­ial25 HVUri­nary catheterizationyes
Med techDeviceCatheter Mate­r­ial25 HVUri­nary catheterizationyes
Med techDeviceCatheter Mate­r­ial25 HVUri­nary catheterizationyes
Med techDeviceMigraine12 HVNasal stim­u­la­tionYes
Med techDeviceMigraine12 HVEar stim­u­la­tionYes
I (poM)CNSAlzheimer18 HVPET studyYes
I (poM)CNSSchiz­o­phre­nia12 HVPET studyYes
I (poM)CNSParkinson´s Dis­ease15 HVPETYes
ObsPsy­chi­a­tryDepres­sion50 HVRecruit­ning healthy con­trol groupYes
IIPul­monaryAllergy6 patUnblinded part of studyOngo­ing
FIMMeta­bolicPorfyria27 patFirst in patient SAD and MADOngo­ing
IVac­cineB. Per­tus­siss54 HVMADOngo­ing

Kon­takt Fas 1

Har­riet Udd

Tel:+46 (0)8517 782 11
Mobil:+46 (0)70168 49 54
harriet.​udd@​karolinska.​se